Table 4.

A. Associations between haplotypes in GH1 and breast cancer risk and IGF-I and IGFBP-3 levels adjusted for age and center
GH1 haplotypes*Haplotype frequencyModel
CodominantDominantRecessive
hGGAA0.33OR (95% CI)1.001.001.00
α IGF-I (P)434.39433.82428.42
α IGFBP-3 (P)2,5232,5212,480
hTAAT0.29OR (95% CI)1.03 (0.88-1.21)1.05 (0.86-1.28)1.00 (0.74-1.36)
β IGF-I (P)−5.31 (0.04)−6.44 (0.05)−1.27 (0.81)
β IGFBP-3 (P)−40.88 (0.11)−57.86 (0.07)22.66 (0.66)
hGAAT0.17OR (95% CI)1.13 (0.94-1.36)1.13 (0.92-1.40)1.29 (0.80-2.09)
β IGF-I (P)−0.88 (0.77)0.50 (0.88)0.68 (0.94)
β IGFBP-3 (P)−36.66 (0.23)−19.12 (0.58)−119.97 (0.14)
hGGAT0.09OR (95% CI)0.94 (0.73-1.22)0.96 (0.73-1.26)0.35 (0.08-1.54)
β IGF-I (P)−7.00 (0.10)−4.78 (0.29)−41.98 (0.02)
β IGFBP-3 (P)−81.60 (0.05)−71.75 (0.11)−272.79 (0.14)
hGAAA0.06OR (95% CI)0.97 (0.71-1.34)0.98 (0.70-1.38)0.76 (0.20-2.90)
β IGF-I (P)−13.42 (0.01)−13.59 (0.02)−17.80 (0.42)
β IGFBP-3 (P)−71.15 (0.17)−71.47 (0.20)−109.74 (0.61)
hTAAA0.03OR (95% CI)1.01 (0.66-1.54)1.03 (0.67-1.60)
β IGF-I (P)−3.94 (0.58)−1.36 (0.85)−32.42 (0.51)
β IGFBP-3 (P)−23.85 (0.73)−0.95 (0.99)−216.23 (0.66)
hTGAT0.02OR (95% CI)1.02 (0.56-1.86)1.01 (0.56-1.84)
β IGF-I (P)−10.66 (0.29)−9.60 (0.34)
β IGFBP-3 (P)77.03 (0.44)91.97 (0.35)
B. Associations between haplotypes in GHRHR and breast cancer risk and IGF-I and IGFBP-3 levels adjusted for age and center
GHRHR haplotypes§
Haplotype frequency
Model
Codominant
Dominant
Recessive
hCGTCC0.57OR (95% CI)1.001.001.00
α IGF-I (P)430.56430.14428.99
α IGFBP-3 (P)2,4592,4652,466
hCGCCG0.24OR (95% CI)0.94 (0.81-1.10)0.98 (0.81-1.19)0.73 (0.49-1.09)
β IGF-I (P)−1.36 (0.59)−0.84 (0.78)−2.91 (0.64)
β IGFBP-3 (P)30.35 (0.22)23.01 (0.44)99.56 (0.11)
hCGTTC0.10OR (95% CI)1.19 (0.95-1.49)1.23 (0.95-1.59)1.51 (0.66-3.45)
β IGF-I (P)−4.15 (0.23)−3.61 (0.33)−15.08 (0.30)
β IGFBP-3 (P)17.24 (0.62)20.91 (0.57)−91.26 (0.52)
hTATCG0.05OR (95% CI)0.78 (0.59-1.04)0.79 (0.59-1.07)0.67 (0.07-6.41)
β IGF-I (P)1.61 (0.73)1.18 (0.80)8.01 (0.82)
β IGFBP-3 (P)46.45 (0.30)37.44 (0.42)435.63 (0.20)
hCGCCC0.02OR (95% CI)1.14 (0.72-1.82)1.15 (0.72-1.84)
β IGF-I (P)−10.20 (0.19)−9.98 (0.20)
β IGFBP-3 (P)−20.06 (0.79)−23.03 (0.76)
C. Associations between haplotypes in SST and breast cancer risk and IGF-I and IGFBP-3 levels adjusted for age and center
SST haplotypes
Haplotype frequency
Model
Codominant
Dominant
Recessive
hTT0.88OR (95% CI)**1.001.001.00
α IGF-I (P)428.40428.49428.19
α IGFBP-3 (P)2,4912,4902,496
hCC0.10OR (95% CI)**1.24 (1.01-1.52)1.27 (1.02-1.59)1.21 (0.52-2.80)
β IGF-I (P)−2.97 (0.39)−4.13 (0.27)10.08 (0.49)
β IGFBP-3 (P)41.17 (0.23)52.56 (0.15)−62.19 (0.66)
hCT0.02OR (95% CI)**1.06 (0.66-1.70)1.08 (0.67-1.75)
β IGF-I (P)−2.62 (0.74)−2.42 (0.76)−23.52 (0.74)
β IGFBP-3 (P)−62.23 (0.43)−63.18 (0.43)−113.09 (0.87)
D. Associations between haplotypes in SSTR2 and breast cancer risk and IGF-I and IGFBP-3 levels adjusted for age and center
SSTR2 haplotypes††
Haplotype frequency
Model
Codominant
Dominant
Recessive
hAC0.43OR (95% CI)‡‡1.001.001.00
α IGF-I (P)426.30426.05423.80
α IGFBP-3 (P)2,4672,4592,460
hGG0.33OR (95% CI)‡‡1.15 (0.99-1.33)1.24 (1.03-1.51)1.03 (0.78-1.36)
β IGF-I (P)−2.49 (0.31)−3.16 (0.32)−0.73 (0.88)
β IGFBP-3 (P)−26.07 (0.29)−27.42 (0.39)−45.40 (0.34)
hAG0.24OR (95% CI)‡‡1.13 (0.96-1.33)1.19 (0.99-1.45)0.96 (0.66-1.40)
β IGF-I (P)−2.44 (0.37)−1.13 (0.73)−8.17 (0.20)
β IGFBP-3 (P)13.67 (0.61)35.75 (0.26)−31.47 (0.61)
E. Associations between haplotypes in SSTR5 and breast cancer risk and IGF-I and IGFBP-3 levels adjusted for age and center
SSTR5 haplotypes§§
Haplotype frequency
Model
Codominant
Dominant
Recessive
hCCTG0.54OR (95% CI)∥∥1.001.001.00
α IGF-I (P)422.66422.52425.75
α IGFBP-3 (P)2,4282,4392,412
hCCCG0.33OR (95% CI)∥∥1.05 (0.91-1.22)1.05 (0.86-1.27)1.12 (0.85-1.49)
β IGF-I (P)−0.32 (0.89)0.16 (0.96)−2.99 (0.53)
β IGFBP-3 (P)−15.32 (0.51)−26.41 (0.40)−0.45 (0.99)
hACCG0.06OR (95% CI)∥∥1.29 (0.85-1.96)1.32 (0.85-2.05)1.00 (0.09-11.03)
β IGF-I (P)−4.32 (0.39)−3.74 (0.46)−40.04 (0.32)
β IGFBP-3 (P)−3.77 (0.94)3.13 (0.95)−537.71 (0.17)
hCTCG0.05OR (95% CI)∥∥0.82 (0.60-1.13)0.81 (0.58-1.11)0.78 (0.13-4.53)
β IGF-I (P)6.22 (0.21)6.73 (0.20)7.92 (0.76)
β IGFBP-3 (P)−18.35 (0.71)−31.90 (0.54)311.84 (0.23)
hCCCA0.03OR (95% CI)∥∥0.90 (0.60-1.34)0.87 (0.57-1.33)1.21 (0.20-7.42)
β IGF-I (P)19.75 (0.002)21.10 (0.002)32.61 (0.29)
β IGFBP-3 (P)2.53 (0.97)−3.51 (0.96)138.88 (0.65)
  • * The order of the SNPs defining the haplotypes is rs2005172, rs6171, rs6173, rs2665802.

  • Reference group = hGGAA.

  • β estimate for IGF-I and IGFBP-3 levels (in ng/mL) for a one-unit change in haplotype dosage adjusted for age and center.

  • § The order of the SNPs defining the haplotypes is rs4988495, rs4988496, rs4988501, rs4988503, rs4988505.

  • Reference group = hCGTCC.

  • The order of the SNPs defining the haplotypes is rs4988513, P0689.

  • ** Reference group = hTT.

  • †† The order of the SNPs defining the haplotypes is rs998571, rs1466113.

  • ‡‡ Reference group = hAC.

  • §§ The order of the SNPs defining the haplotypes is rs4988483, rs4988487, rs169068, rs642249.

  • ∥∥ Reference group = hCCTG.